Annie Chiu

Annie Chiu currently serves as the Associate Director of Process Development at Cargo Therapeutics. In this role, she leads the late-stage process development efforts for the company's flagship program, Firicabtagene Autoleucel (Firi-cel), a CD22-directed CAR T cell therapy. Annie's first exposure that sparked her interest in cell therapy was working in Hans-Peter Kiem's lab at the Fred Hutchinson Cancer Research Center on genetically modified HSCs and large animal models. After obtaining her PhD from the University of California-Davis, Annie's industry experiences have included significant contributions to early process development initiatives in allogeneic CAR NK work at Nkarta and programs utilizing genetically modified HSCs at Orchard Therapeutics.